Thomas C Williams, Steve Cunningham, Simon B Drysdale, Helen Groves, Dalia Iskander, Xinxue Liu, Mark D Lyttle, Robin Marlow, Abigail Maxwell-Hodkinson, Chengetai D Mpamhanga, Shaun O'Hagan, Ian Sinha, Olivia V Swann, Thomas Waterfield, Damian Roland
{"title":"BronchStart - COVID-19 大流行对呼吸道合胞病毒 (RSV) 急诊发病的时间、年龄和严重程度的影响；一项多中心前瞻性观察队列研究 \"的研究预案。","authors":"Thomas C Williams, Steve Cunningham, Simon B Drysdale, Helen Groves, Dalia Iskander, Xinxue Liu, Mark D Lyttle, Robin Marlow, Abigail Maxwell-Hodkinson, Chengetai D Mpamhanga, Shaun O'Hagan, Ian Sinha, Olivia V Swann, Thomas Waterfield, Damian Roland","doi":"10.12688/wellcomeopenres.16778.3","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>In 2021 we launched the BronchStart study, which collected information on 17,899 presentations in children with serious respiratory tract infections following the release of lockdown restrictions. Our study informed the Joint Committee on Vaccination and Immunisation's decision to recommend the introduction maternal respiratory syncytial virus (RSV) vaccination, which was introduced in the United Kingdom in August/September 2024.</p><p><strong>Study question: </strong>We modified our original protocol to conduct a United Kingdom-wide assessment of maternal vaccination against RSV.</p><p><strong>Methods and likely impact: </strong>We will conduct a multi-centre study, utilising the PERUKI network used in the original BronchStart study, to assess the effectiveness of maternal vaccination using a test-negative study design. We will gather detailed clinical information on children admitted with bronchiolitis in the post-RSV vaccination era, and understand possible reasons for incomplete vaccine uptake.</p>","PeriodicalId":23677,"journal":{"name":"Wellcome Open Research","volume":"6 ","pages":"120"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378404.2/pdf/","citationCount":"0","resultStr":"{\"title\":\"Update to: Study Pre-protocol for \\\"BronchStart - The Impact of the COVID-19 Pandemic on the Timing, Age and Severity of Respiratory Syncytial Virus (RSV) Emergency Presentations; a Multi-Centre Prospective Observational Cohort Study\\\".\",\"authors\":\"Thomas C Williams, Steve Cunningham, Simon B Drysdale, Helen Groves, Dalia Iskander, Xinxue Liu, Mark D Lyttle, Robin Marlow, Abigail Maxwell-Hodkinson, Chengetai D Mpamhanga, Shaun O'Hagan, Ian Sinha, Olivia V Swann, Thomas Waterfield, Damian Roland\",\"doi\":\"10.12688/wellcomeopenres.16778.3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>In 2021 we launched the BronchStart study, which collected information on 17,899 presentations in children with serious respiratory tract infections following the release of lockdown restrictions. Our study informed the Joint Committee on Vaccination and Immunisation's decision to recommend the introduction maternal respiratory syncytial virus (RSV) vaccination, which was introduced in the United Kingdom in August/September 2024.</p><p><strong>Study question: </strong>We modified our original protocol to conduct a United Kingdom-wide assessment of maternal vaccination against RSV.</p><p><strong>Methods and likely impact: </strong>We will conduct a multi-centre study, utilising the PERUKI network used in the original BronchStart study, to assess the effectiveness of maternal vaccination using a test-negative study design. We will gather detailed clinical information on children admitted with bronchiolitis in the post-RSV vaccination era, and understand possible reasons for incomplete vaccine uptake.</p>\",\"PeriodicalId\":23677,\"journal\":{\"name\":\"Wellcome Open Research\",\"volume\":\"6 \",\"pages\":\"120\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-10-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378404.2/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Wellcome Open Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.12688/wellcomeopenres.16778.3\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Wellcome Open Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12688/wellcomeopenres.16778.3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
Update to: Study Pre-protocol for "BronchStart - The Impact of the COVID-19 Pandemic on the Timing, Age and Severity of Respiratory Syncytial Virus (RSV) Emergency Presentations; a Multi-Centre Prospective Observational Cohort Study".
Background: In 2021 we launched the BronchStart study, which collected information on 17,899 presentations in children with serious respiratory tract infections following the release of lockdown restrictions. Our study informed the Joint Committee on Vaccination and Immunisation's decision to recommend the introduction maternal respiratory syncytial virus (RSV) vaccination, which was introduced in the United Kingdom in August/September 2024.
Study question: We modified our original protocol to conduct a United Kingdom-wide assessment of maternal vaccination against RSV.
Methods and likely impact: We will conduct a multi-centre study, utilising the PERUKI network used in the original BronchStart study, to assess the effectiveness of maternal vaccination using a test-negative study design. We will gather detailed clinical information on children admitted with bronchiolitis in the post-RSV vaccination era, and understand possible reasons for incomplete vaccine uptake.
Wellcome Open ResearchBiochemistry, Genetics and Molecular Biology-Biochemistry, Genetics and Molecular Biology (all)
CiteScore
5.50
自引率
0.00%
发文量
426
审稿时长
1 weeks
期刊介绍：
Wellcome Open Research publishes scholarly articles reporting any basic scientific, translational and clinical research that has been funded (or co-funded) by Wellcome. Each publication must have at least one author who has been, or still is, a recipient of a Wellcome grant. Articles must be original (not duplications). All research, including clinical trials, systematic reviews, software tools, method articles, and many others, is welcome and will be published irrespective of the perceived level of interest or novelty; confirmatory and negative results, as well as null studies are all suitable. See the full list of article types here. All articles are published using a fully transparent, author-driven model: the authors are solely responsible for the content of their article. Invited peer review takes place openly after publication, and the authors play a crucial role in ensuring that the article is peer-reviewed by independent experts in a timely manner. Articles that pass peer review will be indexed in PubMed and elsewhere. Wellcome Open Research is an Open Research platform: all articles are published open access; the publishing and peer-review processes are fully transparent; and authors are asked to include detailed descriptions of methods and to provide full and easy access to source data underlying the results to improve reproducibility.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
